Pfizer's blood cancer drug Bosulif effective in untreated patients

Dec 5 (Reuters) - Pfizer Inc said on Monday its cancer drug, Bosulif, was found effective in a late-stage study on previously untreated patients with a form of blood and bone marrow cancer that is characterized by the abnormal production of white blood cells.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.